Trump said you could learn something from this man

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Daniel Bradbury Biography and Net Worth

Director of Castle Biosciences

Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Since June 2018, Mr. Bradbury has served as Chief Executive Officer of Equillium, Inc., a publicly traded biotechnology company, where he also served as its President from March 2017 until June 2018. Mr. Bradbury is the founder of, and has served as the managing member of, BioBrit, LLC, a life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc. from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the board of directors of numerous private companies and two publicly traded companies, Equillium, Inc. and Intercept Pharmaceuticals, Inc. He previously served on the board of directors of the following publicly traded companies: Corcept Therapeutics, Inc., from 2012 to 2019; Geron Corporation, from 2012 to 2019; and Illumina, Inc. from 2004 to 2017. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

What is Daniel Bradbury's net worth?: The estimated net worth of Daniel Bradbury is at least $162,165.00 as of October 7th, 2024. Mr. Bradbury owns 5,700 shares of Castle Biosciences stock worth more than $162,165 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Bradbury may own. Learn More about Daniel Bradbury's net worth.
How do I contact Daniel Bradbury?: The corporate mailing address for Mr. Bradbury and other Castle Biosciences executives is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. Castle Biosciences can also be reached via phone at (866) 788-9007 and via email at [email protected]. Learn More on Daniel Bradbury's contact information.
Has Daniel Bradbury been buying or selling shares of Castle Biosciences?: During the last ninety days, Daniel Bradbury has sold $231,604.48 in Castle Biosciences stock. Most recently, Daniel Bradbury sold 7,867 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $29.44, for a transaction totalling $231,604.48. Following the completion of the sale, the director now directly owns 5,700 shares of the company's stock, valued at $167,808. Learn More on Daniel Bradbury's trading history.
Who are Castle Biosciences' active insiders?: Castle Biosciences' insider roster includes Daniel Bradbury (Director), Jeffrey Eberwein (CEO), Tobin Juvenal (Insider), David Kabakoff (Director), Derek Maetzold (Insider), Kristen Oelschlager (COO), Bernhard Spiess (Insider), Frank Stokes (CFO), and Adam Sussman (Director). Learn More on Castle Biosciences' active insiders.
Are insiders buying or selling shares of Castle Biosciences?: During the last year, insiders at the sold shares 44 times. They sold a total of 233,784 shares worth more than $5,324,298.53. The most recent insider tranaction occured on November, 15th when CFO Frank Stokes sold 6,923 shares worth more than $207,205.39. Insiders at Castle Biosciences own 7.2% of the company. Learn More about insider trades at Castle Biosciences.
Information on this page was last updated on 11/15/2024.

Daniel Bradbury Insider Trading History at Castle Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/7/2024	Sell	7,867	$29.44	$231,604.48	5,700
8/12/2024	Sell	7,883	$26.65	$210,081.95	8,550
5/6/2024	Sell	23,323	$24.64	$574,678.72	9,981
4/8/2024	Sell	2,400	$20.45	$49,080.00	17,944
4/4/2024	Sell	9,152	$21.45	$196,310.40	22,782
3/4/2024	Sell	23,323	$20.68	$482,319.64	25,907
2/7/2024	Sell	2,074	$23.20	$48,116.80	33,870
1/4/2024	Sell	18,223	$20.40	$371,749.20	43,574
12/12/2023	Sell	1,200	$20.01	$24,012.00	50,195
12/8/2023	Sell	6,875	$20.09	$138,118.75	50,605
12/6/2023	Sell	200	$20.02	$4,004.00	52,952
12/4/2023	Sell	4,340	$20.08	$87,147.20	53,020
12/1/2023	Sell	9,545	$20.05	$191,377.25	54,502
11/29/2023	Sell	17,342	$20.12	$348,921.04	60,197
11/24/2023	Sell	800	$20.02	$16,016.00	63,665
11/20/2023	Sell	5,755	$20.04	$115,330.20	63,885
9/1/2023	Sell	1,802	$20.04	$36,112.08	65,037
8/30/2023	Sell	4,632	$20.03	$92,778.96	66,854
7/7/2023	Sell	50,000	$20.39	$1,019,500.00	67,780
5/4/2023	Sell	17,643	$21.69	$382,676.67	79,251
4/5/2023	Sell	7,100	$22.20	$157,620.00	82,780
4/3/2023	Sell	10,300	$22.14	$228,042.00	85,720
3/2/2023	Sell	11,349	$23.30	$264,431.70	90,510
1/3/2023	Sell	7,704	$22.89	$176,344.56	199,539
10/3/2022	Sell	7,704	$27.17	$209,317.68	222,651
8/1/2022	Sell	7,704	$27.47	$211,628.88	238,059
3/29/2022	Sell	8,852	$45.32	$401,172.64
3/14/2022	Sell	8,852	$38.21	$338,234.92
2/22/2022	Sell	8,852	$39.02	$345,405.04
2/9/2022	Sell	8,852	$46.53	$411,883.56
1/24/2022	Sell	14,631	$35.42	$518,230.02
1/20/2022	Sell	15,604	$35.26	$550,197.04
1/18/2022	Sell	2,470	$35.30	$87,191.00
1/4/2022	Sell	16,353	$43.58	$712,663.74
11/8/2021	Sell	5,554	$61.21	$339,960.34
11/4/2021	Sell	4,446	$61.05	$271,428.30
10/21/2021	Sell	5,000	$62.94	$314,700.00
10/4/2021	Sell	5,000	$60.93	$304,650.00
9/21/2021	Sell	5,000	$73.95	$369,750.00
8/17/2021	Sell	644	$60.02	$38,652.88
8/3/2021	Sell	5,000	$69.62	$348,100.00
7/26/2021	Sell	5,000	$66.78	$333,900.00
7/8/2021	Sell	5,000	$69.56	$347,800.00
4/22/2021	Sell	15,000	$63.69	$955,350.00
4/7/2021	Sell	15,000	$72.81	$1,092,150.00
3/24/2021	Sell	7,500	$63.09	$473,175.00
2/23/2021	Sell	7,500	$79.63	$597,225.00
2/10/2021	Sell	15,000	$95.35	$1,430,250.00
1/25/2021	Sell	7,500	$76.94	$577,050.00
1/12/2021	Sell	12,113	$78.29	$948,326.77
12/29/2020	Sell	30,000	$69.69	$2,090,700.00
10/20/2020	Sell	11,750	$49.70	$583,975.00
9/16/2020	Sell	3,750	$48.38	$181,425.00
9/2/2020	Sell	7,500	$45.66	$342,450.00
8/18/2020	Sell	3,750	$43.18	$161,925.00
8/6/2020	Sell	3,750	$41.34	$155,025.00
7/21/2020	Sell	3,750	$41.81	$156,787.50
7/8/2020	Sell	7,500	$41.08	$308,100.00
6/3/2020	Sell	3,750	$37.01	$138,787.50
5/21/2020	Sell	3,750	$37.21	$139,537.50	208,053

Daniel Bradbury Buying and Selling Activity at Castle Biosciences

Castle Biosciences Company Overview

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Today's Range

Now: $28.45

$27.68

$28.80

50 Day Range

MA: $31.05

$27.86

$34.67

2 Week Range

Now: $28.45

$16.97

$35.84

Volume

309,760 shs

Average Volume

327,497 shs

Market Capitalization

$796.88 million

P/E Ratio

142.26

Dividend Yield

N/A

Beta

0.99

Trump said you could learn something from this man

From Wide Moat Research | Ad

Here’s everything you need to know.